Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

← catalyst calendar

NCT05379985 · readout in 285 d

Sponsored by Revolution Medicines, Inc. (industry) · RVMD — their whole pipeline →.

Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
754estimated
Sites
21
Country
United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2022-05-31actualWhen the study began enrolling
Primary completion2027-05-31estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completion2027-07-26estimatedThe whole study's end, after follow-up
First posted2022-05-18actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-05-15actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

  • Non-small Cell Lung Cancer (NSCLC)
  • Colorectal Cancer (CRC)
  • Pancreatic Ductal Adenocarcinoma (PDAC)
  • Advanced Solid Tumors

Intervention

  • Drug: RMC-6236

Primary outcomes

what the primary-completion date above is the date OF
Incidence and severity of treatment-emergent Adverse Events (AEs) and serious AEs, including incidence and severity of findings in laboratory values and vital signs
measured up to 2.5 years
Number of Participants with Dose-Limiting Toxicity (DLT)
measured 21 days

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · RVMD's whole pipeline · Catalyst calendar · Every registered study · What changed